A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

This study is a single-center, open-label, dose-escalation study to observe the safety and efficacy of different doses of CAR-GPRC5D in patients with R/R MM or Plasma Cell Leukemia.

Trial Details

NCT ID
NCT05759793
Phase
PHASE1
Sponsor
Nanjing IASO Biotechnology Co., Ltd.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CAR-GPRC5D
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Subjects must satisfy all the following criteria to be enrolled in the study:
  • age 18 to 75 years old, male or female.
  • Subjects have had at least 3 prior lines of therapy including chemotherapy based on proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs).
  • According to the International Myeloma Working Group (IMWG) consensus (2016) standard on multiple myeloma, the disease has recurred, progressed or …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →